Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Endocrine. 2013 Nov 28;46(2):318–327. doi: 10.1007/s12020-013-0093-x

Table 2.

Postoperative features

Outcome Number of patients with feature/total number of patients with available data (%)
Post-operative use of DA 11/23 (48)
Subjects with persistent post-operative PRL hypersecretion 13/26 (50)
Any post-operative hypopituitarism 6/29 (21)
    ACTH deficiency 2/17 (12)
    TSH deficiency 4/17 (24)
    GH deficiency 1/16 (6)
    FSH/LH deficiency 3/11 (27)
Tumor histology
Atypical adenomas 3/26 (12)
Positive p53 6/12 (50)
Increased mitoses 6/11 (55)
Radiologic follow up
Post-operative residual adenoma 11/20 (55)
Growth of post-operative residual on MRI 4/9 (44)
De novo MRI recurrences 3/8 (38)